bluebird bio, Inc. (BLUE): Price and Financial Metrics


bluebird bio, Inc. (BLUE): $28.78

0.66 (+2.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

BLUE Stock Summary

  • BLUE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 16.09% of US stocks.
  • Revenue growth over the past 12 months for bluebird bio Inc comes in at 461.25%, a number that bests 98.49% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BLUE comes in at -28.96% -- higher than that of only 8.96% of stocks in our set.
  • Stocks that are quantitatively similar to BLUE, based on their financial statements, market capitalization, and price volatility, are CYCN, MRKR, EVGN, KLDO, and TBPH.
  • Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to www.bluebirdbio.com.

BLUE Stock Price Chart Interactive Chart >

Price chart for BLUE

BLUE Price/Volume Stats

Current price $28.78 52-week high $72.50
Prev. close $28.12 52-week low $24.24
Day low $27.54 Volume 872,944
Day high $28.95 Avg. volume 2,153,434
50-day MA $30.37 Dividend yield N/A
200-day MA $47.48 Market Cap 1.93B

bluebird bio, Inc. (BLUE) Company Bio


Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.


BLUE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream


Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

Bluebird bio price target slashed at Stifel after setback in Germany

The decision by bluebird bio ([[BLUE]] +0.1%) to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (“TDT”) from the German market did not come as a surprise.A Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) forced a temporary suspension of two clinical trials in sickle cell disease for its...

Seeking Alpha | April 20, 2021

bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations

bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disease (SCD) (bb1111), the company’s decision to withdraw ZYNTEGLO™ (betibeglogene autotemcel, beti-cel) for transfusion-dependent β-thalassemia (TDT) from the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs.

Yahoo | April 20, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of bluebird bio, Inc. ("bluebird") (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To ...

Yahoo | April 13, 2021

BLUE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Lead Plaintiff Deadline April 13, 2021

NEW YORK, NY / ACCESSWIRE / April 13, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired bluebird securities between May 11, 2020 and November 4, 2020, both dates inclusive (the "Class Period").

Yahoo | April 13, 2021

BlueBird Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses of over $100,000 are encouraged to contact the firm before April 13, 2021; click here to submit trade informationLOS ANGELES, April 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BlueBird Bio, Inc. (NASDAQ: BLUE) investors that acquired shares between May 11, 2020 and November 4, 2020. Investors have until April 13, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that Bluebird made misleading and false statements to the market. Bluebird presented insufficient data to support it...

Yahoo | April 13, 2021

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo -1.77%
3-mo -38.29%
6-mo -48.17%
1-year -48.22%
3-year -82.89%
5-year -42.81%
YTD -33.49%
2020 -50.69%
2019 -11.54%
2018 -44.30%
2017 188.65%
2016 -3.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0741 seconds.